In cancer cells with homologous recombination (HR) defects—such as BRCA1/2-mutant tumours—PARP inhibition induces synthetic lethality by converting unrepaired SSBs into lethal DSBs that cannot be efficiently repaired.75 The gene discussed is PARP1; the disease is cancer.